ProteinQure

Note: This article was tagged for deletion on Wikipedia under Criteria for speedy deletion (CSD): No indication of importance (A7).

ProteinQure Inc. is a Canadian biotechnology company based in Toronto, Ontario, focused on the computational design of peptide therapeutics and peptide–drug conjugates.

The company's lead programme, PQ203, is a peptide–drug conjugate being evaluated in a Phase I clinical trial for advanced malignant tumours, including triple-negative breast cancer.

History

ProteinQure Inc. was incorporated under the Canada Business Corporations Act on 24 October 2017. The company was founded in 2017 by Lucas Siow, Tomas Babej, Christopher Ing, and Mark Fingerhuth.

In July 2019, BetaKit reported that ProteinQure raised CAD $5.2 million in seed financing led by Felicis Ventures, with participation from 8VC, Golden Ventures, iNovia, Global Founders Capital, and angel investor Tom Williams.

In July 2020, the company announced a research collaboration with AstraZeneca focused on peptide therapeutic design.

In May 2025, BetaKit reported that the company raised a US$11 million Series A financing round to support initiation of clinical testing for PQ203.

Research and development

ProteinQure develops computational platforms for peptide therapeutic design, integrating machine learning and structure-based drug design approaches.

Its lead candidate, PQ203, is a peptide–drug conjugate targeting the sortilin receptor (SORT1) and conjugated to the cytotoxic agent Monomethyl auristatin E (MMAE), according to company disclosures. The Phase I study is registered on ClinicalTrials.gov as NCT07190469.